Advances and gaps in SARS-CoV-2 infection models
C Muñoz-Fontela, L Widerspick, RA Albrecht… - PLoS …, 2022 - journals.plos.org
The global response to Coronavirus Disease 2019 (COVID-19) is now facing new
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern …
SARS-CoV-2 infection and lung regeneration
F Zhao, Q Ma, Q Yue, H Chen - Clinical Microbiology Reviews, 2022 - Am Soc Microbiol
The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2)-induced immunopathology whereby the virus enters the host cells by binding to …
2)-induced immunopathology whereby the virus enters the host cells by binding to …
A highly photostable and bright green fluorescent protein
M Hirano, R Ando, S Shimozono, M Sugiyama… - Nature …, 2022 - nature.com
The low photostability of fluorescent proteins is a limiting factor in many applications of
fluorescence microscopy. Here we present StayGold, a green fluorescent protein (GFP) …
fluorescence microscopy. Here we present StayGold, a green fluorescent protein (GFP) …
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop
effective countermeasures against the causative viral agent, SARS-CoV-2 and its many …
effective countermeasures against the causative viral agent, SARS-CoV-2 and its many …
The potential of nanobodies for COVID-19 diagnostics and therapeutics
DB Naidoo, AA Chuturgoon - Molecular Diagnosis & Therapy, 2023 - Springer
The infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the
causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been …
causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been …
Therapeutic role of neutralizing antibody for the treatment against SARS-CoV-2 and its emerging variants: A clinical and pre-clinical perspective
Since early 2020, the entire world has been facing a disastrous outbreak of the SARS-CoV-2
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
virus, with massive reporting of death and infections per day. Medical practitioners adopted …
Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: Current update
M Bhattacharya, S Chatterjee, SS Lee… - International Journal of …, 2023 - Elsevier
In the last two years, the world encountered the SARS-CoV-2 virus, which is still dominating
the population due to the absence of a viable treatment. To eradicate the global pandemic …
the population due to the absence of a viable treatment. To eradicate the global pandemic …
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
TR Wagner, D Schnepf, J Beer, N Ruetalo, K Klingel… - EMBO …, 2022 - embopress.org
The ongoing COVID‐19 pandemic and the emergence of new SARS‐CoV‐2 variants of
concern (VOCs) requires continued development of effective therapeutics. Recently, we …
concern (VOCs) requires continued development of effective therapeutics. Recently, we …
Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review
Purpose The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no
completely efficient treatment has yet been found. Antibody therapy is one way to control …
completely efficient treatment has yet been found. Antibody therapy is one way to control …
First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
A Titong, S Gallolu Kankanamalage, J Dong… - Scientific Reports, 2022 - nature.com
SARS-CoV-2 and its variants have persisted in this ongoing COVID-19 pandemic. While the
vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half …
vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half …